{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and document_type = \"Supporting & Related Material\" sorted by posted_date descending", "rows": [["FDA-2026-P-2144-0003", "FDA", "FDA-2026-P-2144", "Attachment 1", "Supporting & Related Material", "Background Material", "2026-02-27T05:00:00Z", 2026, 2, null, null, "2026-02-27T22:06:13Z", null, 0, 0, "09000064b91e2fca"], ["FDA-2026-P-2144-0005", "FDA", "FDA-2026-P-2144", "Attachment 3", "Supporting & Related Material", "Background Material", "2026-02-27T05:00:00Z", 2026, 2, null, null, "2026-02-27T22:06:19Z", null, 0, 0, "09000064b91e2fcc"], ["FDA-2026-P-1300-0006", "FDA", "FDA-2026-P-1300", "Attachment 1 - RLD BELSOMRA\u00ae (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Package Insert", "Supporting & Related Material", "Background Material", "2026-02-27T05:00:00Z", 2026, 2, null, null, "2026-02-27T23:32:57Z", null, 0, 0, "09000064b91e3e19"], ["FDA-2026-P-1300-0007", "FDA", "FDA-2026-P-1300", "Attachment 2 - RLD BELSOMRA\u00ae (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Approval Letter", "Supporting & Related Material", "Background Material", "2026-02-27T05:00:00Z", 2026, 2, null, null, "2026-02-27T23:33:00Z", null, 0, 0, "09000064b91e3e1a"], ["FDA-2026-P-2144-0004", "FDA", "FDA-2026-P-2144", "Attachment 2", "Supporting & Related Material", "Background Material", "2026-02-27T05:00:00Z", 2026, 2, null, null, "2026-02-27T22:06:16Z", null, 0, 0, "09000064b91e2fcb"], ["FDA-2026-P-2004-0004", "FDA", "FDA-2026-P-2004", "Attachment 2", "Supporting & Related Material", "Background Material", "2026-02-25T05:00:00Z", 2026, 2, null, null, "2026-02-25T23:22:03Z", null, 0, 0, "09000064b91dab5d"], ["FDA-2026-P-2004-0005", "FDA", "FDA-2026-P-2004", "Attachment 3", "Supporting & Related Material", "Background Material", "2026-02-25T05:00:00Z", 2026, 2, null, null, "2026-02-25T23:22:06Z", null, 0, 0, "09000064b91dab5e"], ["FDA-2026-P-2004-0003", "FDA", "FDA-2026-P-2004", "Attachment 1", "Supporting & Related Material", "Background Material", "2026-02-25T05:00:00Z", 2026, 2, null, null, "2026-02-25T23:22:01Z", null, 0, 0, "09000064b91dab5c"], ["FDA-2025-P-4282-0172", "FDA", "FDA-2025-P-4282", "Reference 27 - Large - Violence in first-episode psychosis A systematic review and meta-analysis", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:10Z", null, 0, 0, "09000064b91d3d7f"], ["FDA-2025-P-4282-0154", "FDA", "FDA-2025-P-4282", "Reference 9 - Chalasani - Clozapine Impact on Clinical Outcomes and Aggression in Severely Ill Adolescents with Childhood-Onset Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:18Z", null, 0, 0, "09000064b91d3d6d"], ["FDA-2025-P-4282-0160", "FDA", "FDA-2025-P-4282", "Reference 15 - di Giacomo et al - Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:36Z", null, 0, 0, "09000064b91d3d73"], ["FDA-2025-P-4282-0164", "FDA", "FDA-2025-P-4282", "Reference 19 - Fazel et al - Schizophrenia and Violence Systematic Review and Meta-Analysis", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:49Z", null, 0, 0, "09000064b91d3d77"], ["FDA-2025-P-4282-0167", "FDA", "FDA-2025-P-4282", "Reference 22 - Galletly - Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:57Z", null, 0, 0, "09000064b91d3d7a"], ["FDA-2025-P-4282-0148", "FDA", "FDA-2025-P-4282", "Reference 4 - Bitter - Effectiveness of Clozapine Olanzapine Quetiapine Risperidone and Haloperidol Monotherapy", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:58Z", null, 0, 0, "09000064b91d0f90"], ["FDA-2025-P-4282-0151", "FDA", "FDA-2025-P-4282", "Reference 7 - Cavaliere - Anti-Aggressive Effects of Clozapine in Involuntarily Committed Black Patients with Severe Mental Illness", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:09Z", null, 0, 0, "09000064b91d0f93"], ["FDA-2025-P-4282-0178", "FDA", "FDA-2025-P-4282", "Reference 33 - Sariaslan - Associations between individual antipsychotics and the Risk of Arrests and Convictions of Violent and Other Crime", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:30Z", null, 0, 0, "09000064b91d3d85"], ["FDA-2025-P-4282-0150", "FDA", "FDA-2025-P-4282", "Reference 6 - Buckley - Violence and Schizophrenia Clozapine as a Specific Antiaggressive Agent", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:05Z", null, 0, 0, "09000064b91d0f92"], ["FDA-2025-P-4282-0156", "FDA", "FDA-2025-P-4282", "Reference 11 - Citrome - Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:24Z", null, 0, 0, "09000064b91d3d6f"], ["FDA-2025-P-4282-0158", "FDA", "FDA-2025-P-4282", "Reference 13 - de Domenico - The effect of clozapine of aggressive behaviour in patients with chronic schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:30Z", null, 0, 0, "09000064b91d3d71"], ["FDA-2025-P-4282-0169", "FDA", "FDA-2025-P-4282", "Reference 24 - Herman - Clinical Response to Clozapine Treatment of 11 Chronic Patients in a State Psychiatric Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:02Z", null, 0, 0, "09000064b91d3d7c"], ["FDA-2025-P-4282-0155", "FDA", "FDA-2025-P-4282", "Reference 10 - Chiles - Effects of Clozapine on Use of Seclusion and Restraint at a State Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:21Z", null, 0, 0, "09000064b91d3d6e"], ["FDA-2025-P-4282-0159", "FDA", "FDA-2025-P-4282", "Reference 14 - Dennis - Clozapine Therapy in a State Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:33Z", null, 0, 0, "09000064b91d3d72"], ["FDA-2025-P-4282-0163", "FDA", "FDA-2025-P-4282", "Reference 18 - Fazel Grann - The Population Impact of Severe Mental Illness on Violent Crime", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:46Z", null, 0, 0, "09000064b91d3d76"], ["FDA-2025-P-4282-0168", "FDA", "FDA-2025-P-4282", "Reference 23 - Gammon - Clozapine Why Is It So Uniquely Effective in the Treatment ofa Range of Neuropsychiatric Disorders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:00Z", null, 0, 0, "09000064b91d3d7b"], ["FDA-2025-P-4282-0182", "FDA", "FDA-2025-P-4282", "Reference 37 - Wagner et al - Clozapine Optimization A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:42Z", null, 0, 0, "09000064b91d3d89"], ["FDA-2025-P-4282-0152", "FDA", "FDA-2025-P-4282", "Reference 8 - Clozapine Impact on Clinical Outcomes and Aggression in Severly Ill Adolescents with Childhood-Onset Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:12Z", null, 0, 0, "09000064b91d3d6b"], ["FDA-2025-P-4282-0171", "FDA", "FDA-2025-P-4282", "Reference 26 - Kranzler - Clozapine Its Impact on Aggressive Behavior Among Children and Adolescents with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:08Z", null, 0, 0, "09000064b91d3d7e"], ["FDA-2025-P-4282-0173", "FDA", "FDA-2025-P-4282", "Reference 28 - Newman - Management of Aggression", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:13Z", null, 0, 0, "09000064b91d3d80"], ["FDA-2025-P-4282-0175", "FDA", "FDA-2025-P-4282", "Reference 30 - Potkin - Predicting Suicidal Risk in Schizophrenic and Schizoaffective Patients in a Prospective Two-Year Trial", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:19Z", null, 0, 0, "09000064b91d3d82"], ["FDA-2025-P-4282-0179", "FDA", "FDA-2025-P-4282", "Reference 34 - Shaheen - The Effect of Clozapine on Violence - Aggression in Adults with Mental Illness and Personality Disorders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:33Z", null, 0, 0, "09000064b91d3d86"], ["FDA-2025-P-4282-0181", "FDA", "FDA-2025-P-4282", "Reference 36 - Volavka - Efficacy of Clozapine Olanzapine Risperidone and Haloperidol in Schizophrenia and Schizoaffective Disorder", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:39Z", null, 0, 0, "09000064b91d3d88"], ["FDA-2025-P-4282-0146", "FDA", "FDA-2025-P-4282", "Reference 2 - Barnes - Evidence-based Guidelines for the Pharmacological Treatment of Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:51Z", null, 0, 0, "09000064b91d0f8e"], ["FDA-2025-P-4282-0176", "FDA", "FDA-2025-P-4282", "Reference 31 - Rabinowitz - Effect of clozapine on physical and verbal aggression", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:23Z", null, 0, 0, "09000064b91d3d83"], ["FDA-2025-P-4282-0166", "FDA", "FDA-2025-P-4282", "Reference 21 - Frogley - A systematic review of the evidence of clozapines anti-aggressive effects", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:54Z", null, 0, 0, "09000064b91d3d79"], ["FDA-2025-P-4282-0180", "FDA", "FDA-2025-P-4282", "Reference 35 - Volavka - Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:36Z", null, 0, 0, "09000064b91d3d87"], ["FDA-2025-P-4282-0177", "FDA", "FDA-2025-P-4282", "Reference 32 - Reid - Internet Archive Interlibrary Loan Fulfillment", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:27Z", null, 0, 0, "09000064b91d3d84"], ["FDA-2025-P-4282-0149", "FDA", "FDA-2025-P-4282", "Reference 5 - Buchanan - The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:01Z", null, 0, 0, "09000064b91d0f91"], ["FDA-2025-P-4282-0153", "FDA", "FDA-2025-P-4282", "Reference 8a - Chengappa - Clozapine Its impact on Aggressive Behavior Among Patients in a State Psychiatric Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:15Z", null, 0, 0, "09000064b91d3d6c"], ["FDA-2025-P-4282-0157", "FDA", "FDA-2025-P-4282", "Reference 12 - Citrome - Effects of Clozapine Olanzapine Risperidone and Haloperidol on Hostility Among Patients with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:27Z", null, 0, 0, "09000064b91d3d70"], ["FDA-2025-P-4282-0161", "FDA", "FDA-2025-P-4282", "Reference 16 - Ebrahim - Patient Response to Clozapine in a Forensic Psychiatric Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:41Z", null, 0, 0, "09000064b91d3d74"], ["FDA-2025-P-4282-0165", "FDA", "FDA-2025-P-4282", "Reference 20 - Fazel et al - Violent crime suicide and premature mortality in patients with schizophrenia and related disorders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:51Z", null, 0, 0, "09000064b91d3d78"], ["FDA-2025-P-4282-0170", "FDA", "FDA-2025-P-4282", "Reference 25 - Keepers - The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:05Z", null, 0, 0, "09000064b91d3d7d"], ["FDA-2025-P-4282-0174", "FDA", "FDA-2025-P-4282", "Reference 29 - Nolan - Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and Schizoaffective Disorder", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:16Z", null, 0, 0, "09000064b91d3d81"], ["FDA-2025-P-4282-0145", "FDA", "FDA-2025-P-4282", "Reference 1 - Balbuena - Does Clozapine Promote Employability and Reduce Offending Among Mentally Disordered Offenders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:48Z", null, 0, 0, "09000064b91d0f8d"], ["FDA-2025-P-4282-0147", "FDA", "FDA-2025-P-4282", "Reference 3 - Bhavsar - Clozapine Treatment and Offending A Within-Subject Study of Patients With Psychotic Disorders in Sweden", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:54Z", null, 0, 0, "09000064b91d0f8f"], ["FDA-2025-P-4282-0162", "FDA", "FDA-2025-P-4282", "Reference 17 - Faden - A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:43Z", null, 0, 0, "09000064b91d3d75"], ["FDA-2024-N-1939-0024", "FDA", "FDA-2024-N-1939", "References List for Cottage Cheese Exemption Final Notice", "Supporting & Related Material", "Background Material", "2026-02-20T05:00:00Z", 2026, 2, null, null, "2026-02-20T20:07:25Z", null, 0, 0, "09000064b91c26ff"], ["FDA-2024-N-1939-0025", "FDA", "FDA-2024-N-1939", "Reference 1 - FDA and NCIMS, \u201cProcedures Governing the Cooperative State-Public Health Service/Food and Drug Administration Program of the National Conference on Interstate Milk Shipment (2019 Revision)\u201d, 2019", "Supporting & Related Material", "Background Material", "2026-02-20T05:00:00Z", 2026, 2, null, null, "2026-02-20T20:10:06Z", null, 0, 0, "09000064b91c2701"], ["FDA-2024-N-1939-0026", "FDA", "FDA-2024-N-1939", "Reference 2 - FDA and NCIMS, \u201cMemorandum of Understanding Between the National Conference on Interstate Milk Shipments and the Food and Drug Administration\u201d, 1977", "Supporting & Related Material", "Background Material", "2026-02-20T05:00:00Z", 2026, 2, null, null, "2026-02-20T20:11:46Z", null, 0, 0, "09000064b91c2702"], ["FDA-2024-N-1939-0027", "FDA", "FDA-2024-N-1939", "Reference 3 - FDA, \u201cGrade \u201cA\u201d Pasteurized Milk Ordinance (2019 Revision),\u201d 2019", "Supporting & Related Material", "Background Material", "2026-02-20T05:00:00Z", 2026, 2, null, null, "2026-02-20T20:13:12Z", null, 0, 0, "09000064b91c2703"], ["FDA-2024-N-1939-0028", "FDA", "FDA-2024-N-1939", "Reference 4 - FDA Memorandum, \u201c2023 Revision of the Grade \u201cA\u201d Pasteurized Milk Ordinance (PMO),\u201d M-I-24-02, August 9, 2024", "Supporting & Related Material", "Background Material", "2026-02-20T05:00:00Z", 2026, 2, null, null, "2026-02-20T20:14:35Z", null, 0, 0, "09000064b91c2704"], ["FDA-2024-N-1939-0029", "FDA", "FDA-2024-N-1939", "Reference 5 - FDA, \u201cGrade \u201cA\u201d Pasteurized Milk Ordinance (2023 Revision),\u201d 2023", "Supporting & Related Material", "Background Material", "2026-02-20T05:00:00Z", 2026, 2, null, null, "2026-02-20T20:16:04Z", null, 0, 0, "09000064b91c2705"], ["FDA-2026-P-1819-0004", "FDA", "FDA-2026-P-1819", "Exhibit A", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T23:12:34Z", null, 0, 0, "09000064b91bf192"], ["FDA-2026-P-1833-0004", "FDA", "FDA-2026-P-1833", "Attachment 2 - Current Electronic Edition of the Approved Drug Products with Therapeutic Equivalence Evaluations - Tolmetin Sodium", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-20T00:31:03Z", null, 0, 0, "09000064b91bf195"], ["FDA-2026-P-1790-0003", "FDA", "FDA-2026-P-1790", "Attachment_1_Photographic_Evidence_Pediatric_Scald_Injury", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T18:16:18Z", null, 0, 0, "09000064b91b91c7"], ["FDA-2026-P-1833-0003", "FDA", "FDA-2026-P-1833", "Attachment 1 - Current Electronic Edition of the Approved Drug Products with Therapeutic Equivalence Evaluations", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-20T00:31:00Z", null, 0, 0, "09000064b91bf194"], ["FDA-2026-P-1820-0003", "FDA", "FDA-2026-P-1820", "Attachment 1 - Tolmetin Capsules - OB Page", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T22:23:47Z", null, 0, 0, "09000064b91c1073"], ["FDA-2026-P-1820-0005", "FDA", "FDA-2026-P-1820", "Attachment 3 - RS Approved Labeling", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T22:23:52Z", null, 0, 0, "09000064b91c107e"], ["FDA-2026-P-1792-0005", "FDA", "FDA-2026-P-1792", "Attachment 3 - Draft Package Insert Proposed for Pregabalin Extended-Release Tablets, 247.5 mg, 495 mg and 660 mg", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T17:46:25Z", null, 0, 0, "09000064b91b9245"], ["FDA-2026-P-1833-0005", "FDA", "FDA-2026-P-1833", "Attachment 3 - Prescribing Information Tolmetin Sodium Capsules USP 400 mg", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-20T00:31:07Z", null, 0, 0, "09000064b91bf196"], ["FDA-2026-P-1833-0006", "FDA", "FDA-2026-P-1833", "Attachment 4 - Proposed labeling for Tolmetin Sodium Capsules 600 mg", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-20T00:31:10Z", null, 0, 0, "09000064b91bf197"], ["FDA-2026-P-1820-0004", "FDA", "FDA-2026-P-1820", "Attachment 2 - Tolmetin Tablets 200 mg - OB Page", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T22:23:50Z", null, 0, 0, "09000064b91c1076"], ["FDA-2026-P-1792-0003", "FDA", "FDA-2026-P-1792", "Attachment 1 - Copy of the relevant excerpt from the current electronic Edition of Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T17:46:12Z", null, 0, 0, "09000064b91b9243"], ["FDA-2026-P-1792-0004", "FDA", "FDA-2026-P-1792", "Attachment 2 - Current Package Insert for LYRICA CE\u00ae, NDA#209501", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T17:46:22Z", null, 0, 0, "09000064b91b9244"], ["FDA-2026-P-1819-0003", "FDA", "FDA-2026-P-1819", "Exhibit 1", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T23:12:29Z", null, 0, 0, "09000064b91bf191"], ["FDA-2026-P-1819-0005", "FDA", "FDA-2026-P-1819", "Exhibit B", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T23:12:38Z", null, 0, 0, "09000064b91bf193"], ["FDA-2026-P-1820-0006", "FDA", "FDA-2026-P-1820", "Attachment 4 - Proposed Labeling for Tolmetin Capsules 200 mg", "Supporting & Related Material", "Background Material", "2026-02-19T05:00:00Z", 2026, 2, null, null, "2026-02-19T22:23:54Z", null, 0, 0, "09000064b91c1080"], ["FDA-2026-P-1794-0007", "FDA", "FDA-2026-P-1794", "Attachment 5 Advances in Therapy", "Supporting & Related Material", "Background Material", "2026-02-18T05:00:00Z", 2026, 2, null, null, "2026-02-19T01:52:47Z", null, 0, 0, "09000064b91bb01b"], ["FDA-2026-P-1794-0004", "FDA", "FDA-2026-P-1794", "Attachment 2 Current Package Insert for Xarelto", "Supporting & Related Material", "Background Material", "2026-02-18T05:00:00Z", 2026, 2, null, null, "2026-02-19T01:52:36Z", null, 0, 0, "09000064b91b9bfd"], ["FDA-2026-P-1794-0006", "FDA", "FDA-2026-P-1794", "Attachment 4 Blood Advances", "Supporting & Related Material", "Background Material", "2026-02-18T05:00:00Z", 2026, 2, null, null, "2026-02-19T01:52:44Z", null, 0, 0, "09000064b91bb01a"], ["FDA-2026-P-1794-0005", "FDA", "FDA-2026-P-1794", "Attachment 3 Proposed Package Insert Rivaroxaban ODT", "Supporting & Related Material", "Background Material", "2026-02-18T05:00:00Z", 2026, 2, null, null, "2026-02-19T01:52:40Z", null, 0, 0, "09000064b91b9bfe"], ["FDA-2026-P-1794-0003", "FDA", "FDA-2026-P-1794", "Attachment 1 Copy of Current Orange Book Listing for RLD Xarelto", "Supporting & Related Material", "Background Material", "2026-02-18T05:00:00Z", 2026, 2, null, null, "2026-02-19T01:52:31Z", null, 0, 0, "09000064b91b9bfc"], ["FDA-2026-N-0302-0003", "FDA", "FDA-2026-N-0302", "Reference 1 BHA RFI Prior Sanction Citizen Petition", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T19:21:26Z", null, 0, 0, "09000064b919eb26"], ["FDA-2026-N-0302-0004", "FDA", "FDA-2026-N-0302", "Reference 2 What We Eat in America 2021-2023 Food Categories", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T19:21:40Z", null, 0, 0, "09000064b919eb27"], ["FDA-2026-P-1583-0007", "FDA", "FDA-2026-P-1583", "Reference 4 - Second edition of guidelines for evaluating the efficacy of anthelmintics for dogs and cats", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T23:00:15Z", null, 0, 0, "09000064b91a3353"], ["FDA-2026-P-1583-0004", "FDA", "FDA-2026-P-1583", "Reference 1 - Pathogens in fleas collected from cats and dogs - distribution and prevalence in the UK", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T23:00:06Z", null, 0, 0, "09000064b91a3350"], ["FDA-2026-P-1583-0006", "FDA", "FDA-2026-P-1583", "Reference 3 - Analysis of Dipylidium caninum tapeworms from dogs and cats or their respective fleas", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T23:00:12Z", null, 0, 0, "09000064b91a3352"], ["FDA-2026-P-1583-0005", "FDA", "FDA-2026-P-1583", "Reference 2 - Occurence of Dipylidium caninum in fleas from client-owned cats and dogs in Europe using a new PCR detection assay", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T23:00:09Z", null, 0, 0, "09000064b91a3351"], ["FDA-2026-N-0302-0002", "FDA", "FDA-2026-N-0302", "Reference List for FDA-2026-N-0302", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T19:21:08Z", null, 0, 0, "09000064b919eb25"], ["FDA-2026-N-0302-0005", "FDA", "FDA-2026-N-0302", "Reference 3 Codex General Standard for Food Additives 2025 Food Categories", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T19:21:53Z", null, 0, 0, "09000064b919eb28"], ["FDA-2026-P-1583-0003", "FDA", "FDA-2026-P-1583", "Exhibit A - Statement of Grounds", "Supporting & Related Material", "Background Material", "2026-02-11T05:00:00Z", 2026, 2, null, null, "2026-02-11T23:00:04Z", null, 0, 0, "09000064b91a334f"], ["FDA-2026-P-1534-0003", "FDA", "FDA-2026-P-1534", "Attachment 1 - Change.org - Results page", "Supporting & Related Material", "Background Material", "2026-02-10T05:00:00Z", 2026, 2, null, null, "2026-02-10T22:27:32Z", null, 0, 0, "09000064b919efc7"], ["FDA-2026-P-1537-0004", "FDA", "FDA-2026-P-1537", "Exhibit B", "Supporting & Related Material", "Background Material", "2026-02-10T05:00:00Z", 2026, 2, null, null, "2026-02-10T23:51:47Z", null, 0, 0, "09000064b919a880"], ["FDA-2026-P-1537-0003", "FDA", "FDA-2026-P-1537", "Exhibit A", "Supporting & Related Material", "Background Material", "2026-02-10T05:00:00Z", 2026, 2, null, null, "2026-02-10T23:51:43Z", null, 0, 0, "09000064b919a87f"], ["FDA-2026-P-1450-0004", "FDA", "FDA-2026-P-1450", "Attachment 2 - Premarin Duavive EMA Full Prescribing Information", "Supporting & Related Material", "Background Material", "2026-02-09T05:00:00Z", 2026, 2, null, null, "2026-02-09T23:11:38Z", null, 0, 0, "09000064b919ae02"], ["FDA-1985-P-0507-0002", "FDA", "FDA-1985-P-0507", "Background Material re Citizen Petition from Roxane Laboratories, Inc.", "Supporting & Related Material", "Background Material", "2026-02-09T05:00:00Z", 2026, 2, null, null, "2026-02-09T20:45:13Z", null, 0, 0, "090000648561f5bb"], ["FDA-2026-P-0748-0007", "FDA", "FDA-2026-P-0748", "Attachment 4-RLD PI", "Supporting & Related Material", "Background Material", "2026-02-09T05:00:00Z", 2026, 2, null, null, "2026-02-09T23:30:56Z", null, 0, 0, "09000064b91970f7"], ["FDA-2026-P-1450-0003", "FDA", "FDA-2026-P-1450", "Attachment 1 - Duavee Full Prescribing Information for Citizen Petition 02-08-2026", "Supporting & Related Material", "Background Material", "2026-02-09T05:00:00Z", 2026, 2, null, null, "2026-02-09T23:11:36Z", null, 0, 0, "09000064b919ae01"], ["FDA-2023-P-0172-0039", "FDA", "FDA-2023-P-0172", "Exhibit K_Redacted", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-07T00:02:02Z", null, 0, 0, "09000064b919073e"], ["FDA-2023-P-0172-0028", "FDA", "FDA-2023-P-0172", "Exhibit J", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-06T23:55:17Z", null, 0, 0, "09000064b91904a3"], ["FDA-2026-P-1373-0007", "FDA", "FDA-2026-P-1373", "Exhibit E", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-07T01:59:21Z", null, 0, 0, "09000064b9196c13"], ["FDA-2026-P-1373-0008", "FDA", "FDA-2026-P-1373", "Exhibit A_Redacted", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-07T01:59:26Z", null, 0, 0, "09000064b9196c19"], ["FDA-2026-P-1373-0009", "FDA", "FDA-2026-P-1373", "Exhibit B_Redacted", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-07T01:59:30Z", null, 0, 0, "09000064b9196c1a"], ["FDA-2026-P-1373-0003", "FDA", "FDA-2026-P-1373", "Exhibit A", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-07T01:58:52Z", null, 0, 0, "09000064b9196c08"], ["FDA-2024-C-3384-0005", "FDA", "FDA-2024-C-3384", "Reference 1_Redacted", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-06T20:58:10Z", null, 0, 0, "09000064b91947ed"], ["FDA-2023-P-0172-0023", "FDA", "FDA-2023-P-0172", "Exhibit E", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-06T23:53:08Z", null, 0, 0, "09000064b9190474"], ["FDA-2023-P-0172-0033", "FDA", "FDA-2023-P-0172", "Exhibit C_Redacted", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-06T23:59:17Z", null, 0, 0, "09000064b919070d"], ["FDA-2023-P-0172-0030", "FDA", "FDA-2023-P-0172", "Exhibit L", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-06T23:57:46Z", null, 0, 0, "09000064b9196ddd"], ["FDA-2023-P-0172-0019", "FDA", "FDA-2023-P-0172", "Exhibit A", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-06T23:51:18Z", null, 0, 0, "09000064b919042d"], ["FDA-2023-P-0172-0024", "FDA", "FDA-2023-P-0172", "Exhibit F", "Supporting & Related Material", "Background Material", "2026-02-06T05:00:00Z", 2026, 2, null, null, "2026-02-06T23:53:53Z", null, 0, 0, "09000064b919047a"]], "truncated": false, "filtered_table_rows_count": 55967, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"document_type\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "Supporting & Related Material"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material", "results": [{"value": "FDA", "label": "FDA", "count": 55967, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?document_type=Supporting+%26+Related+Material", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 55967, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA", "selected": true}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material", "results": [{"value": 2016, "label": 2016, "count": 7820, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2016", "selected": false}, {"value": 2014, "label": 2014, "count": 6510, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2014", "selected": false}, {"value": 2017, "label": 2017, "count": 5045, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2017", "selected": false}, {"value": 2015, "label": 2015, "count": 4911, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2015", "selected": false}, {"value": 2024, "label": 2024, "count": 3653, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2024", "selected": false}, {"value": 2025, "label": 2025, "count": 3617, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2025", "selected": false}, {"value": 2018, "label": 2018, "count": 3331, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2018", "selected": false}, {"value": 2022, "label": 2022, "count": 2695, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2022", "selected": false}, {"value": 2020, "label": 2020, "count": 2602, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2020", "selected": false}, {"value": 2019, "label": 2019, "count": 2365, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2019", "selected": false}, {"value": 2023, "label": 2023, "count": 2162, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2023", "selected": false}, {"value": 2008, "label": 2008, "count": 1492, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2008", "selected": false}, {"value": 2021, "label": 2021, "count": 1390, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2021", "selected": false}, {"value": 2009, "label": 2009, "count": 1318, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2009", "selected": false}, {"value": 2003, "label": 2003, "count": 1118, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2003", "selected": false}, {"value": 2004, "label": 2004, "count": 1007, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2004", "selected": false}, {"value": 2010, "label": 2010, "count": 921, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2010", "selected": false}, {"value": 2007, "label": 2007, "count": 905, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2007", "selected": false}, {"value": 2011, "label": 2011, "count": 703, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2011", "selected": false}, {"value": 2006, "label": 2006, "count": 635, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2006", "selected": false}, {"value": 2005, "label": 2005, "count": 494, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2005", "selected": false}, {"value": 2012, "label": 2012, "count": 365, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2012", "selected": false}, {"value": 2026, "label": 2026, "count": 281, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2026", "selected": false}, {"value": 2013, "label": 2013, "count": 222, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2013", "selected": false}, {"value": 2001, "label": 2001, "count": 163, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=2001", "selected": false}, {"value": 1997, "label": 1997, "count": 60, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=1997", "selected": false}, {"value": 1996, "label": 1996, "count": 55, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=1996", "selected": false}, {"value": 1995, "label": 1995, "count": 46, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=1995", "selected": false}, {"value": 1999, "label": 1999, "count": 29, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=1999", "selected": false}, {"value": 1998, "label": 1998, "count": 19, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&posted_year=1998", "selected": false}], "truncated": true}}, "suggested_facets": [], "next": "2026-02-06T05~3A00~3A00Z,FDA-2023-P-0172-0024", "next_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&document_type=Supporting+%26+Related+Material&_next=2026-02-06T05~3A00~3A00Z%2CFDA-2023-P-0172-0024&_sort_desc=posted_date", "private": false, "allow_execute_sql": true, "query_ms": 3139.80266591534, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}